The FDA approved zidesamtinib (Jideytro) on July 22, 2026 for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer whose disease has progressed after a previous ROS1-targeted therapy, per an FDA announcement. The drug had received breakthrough therapy designation, which flags evidence of substantial improvement over available options.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
Why the ROS1 alteration matters
ROS1-positive lung cancer is driven by a rearrangement in the ROS1 gene and accounts for a small share of non-small cell lung cancers, the most common form of the disease. Patients often respond to ROS1 kinase inhibitors, but resistance and brain spread eventually limit the older drugs, so therapies that keep working after the first targeted drug fails are a recognized unmet need, per the agency's description of the approval.
Research on the compound drew on work at Memorial Sloan Kettering Cancer Center, according to the center's report on the decision.
Related stories: FDA Approves Simtriyo, a First-in-Class Nonstimulant Pill for ADHD · FDA Approves First Oral Antiviral to Prevent COVID-19 After Exposure.
What this approval can and cannot show
The approval rests on single-arm trial data, meaning responses are measured without a randomized control group, so the size of benefit relative to alternatives cannot be directly estimated. Duration of response and overall survival will become clearer only with longer follow-up. The indication applies to a specific molecular subgroup identified by biomarker testing, not to lung cancer generally.
When to talk to a clinician
The label also carries warnings that clinicians review before starting therapy, and patients taking other medications should discuss interactions, since targeted agents are processed through liver pathways that many drugs share.
Oncologists use molecular profiling to identify ROS1 rearrangements. Patients whose cancer has progressed on a ROS1 inhibitor can ask whether their tumor has been tested and whether the newly approved option fits their treatment sequence.